This article was originally published in The Tan Sheet
Zinc lozenge marketer plans to have its flagship product "available in the U.K. market and the rest of the EU to follow as a full-blown pharmacy drug," President and CEO Guy Quigley says during a Dec. 7 conference call. Quigley notes the company has just completed a double-blind study, which it regards as the final step in its filing with the U.K. Medicines Control Agency. The launch would mark a shift from homeopathy for the firm. The conference call was held to clarify the terms of the company's recent consent agreement with the FTC (1"The Tan Sheet" Nov. 29, p. 11). Quigley notes the settlement does not prohibit the firm from making claims concerning the duration or severity of the common cold and says the only packaging changes that need to be made involve Sugar-free Cold-Eeze
You may also be interested in...
Quigley Corporation, manufacturer and marketer of the homeopathic Cold-Eeze line of zinc lozenges, and QVC Inc., a television retailing service, have agreed to settle charges they made unsubstantiated claims regarding the product's ability to "prevent colds and alleviate allergy symptoms," the Federal Trade Commission announced Nov. 23.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning